Portage Biotech Inc
NASDAQ:PRTG

Watchlist Manager
Portage Biotech Inc Logo
Portage Biotech Inc
NASDAQ:PRTG
Watchlist
Price: 4.7001 USD -0.84% Market Closed
Market Cap: 10.7m USD

PRTG's latest stock split occurred on Aug 15, 2024

The company executed a 1-for-20 stock split, meaning that for every 20 shares held, investors received 1 new share.

Before the split, PRTG traded at 0.1075 per share. Afterward, the share price was about 3.5.

The adjusted shares began trading on Aug 15, 2024. This was PRTG's 4th stock split, following the previous one in Jun 4, 2020.

Last Splits:
Aug 15, 2024
1-for-20
Jun 4, 2020
1-for-100
Apr 21, 2003
1-for-7
Jan 21, 1999
1-for-15
Pre-Split Price
2.15 0.1075
Post-Split Price
3.5
Before
After
Last Splits:
Aug 15, 2024
1-for-20
Jun 4, 2020
1-for-100
Apr 21, 2003
1-for-7
Jan 21, 1999
1-for-15

Portage Biotech Inc
Stock Splits History

PRTG Stock Splits Timeline
Aug 15, 2024
Aug 15, 2024
Split 1-for-20
/0.05
Pre-Split Price
2.15 0.1075
Post-Split Price
3.5
Before
After
Jun 4, 2020
Jun 4, 2020
Split 1-for-100
/0.01
Pre-Split Price
220 0.11
Post-Split Price
220
Before
After
Apr 21, 2003
Apr 21, 2003
Split 1-for-7
/0.14285714285714
Pre-Split Price
489.8531 0.035
Post-Split Price
490
Before
After
Jan 21, 1999
Jan 21, 1999
Split 1-for-15
/0.066666666666667
Pre-Split Price
14 700.0021 1.05
Post-Split Price
21 000
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Jan 20, 2026
Linius Technologies Ltd
OTC:LNNTF
1-for-100
/100
0.0001 0.0001 USD N/A
Jan 20, 2026
Lotus Resources Ltd
OTC:LTSRF
1-for-11
/11
0.13 0.13 USD N/A
Jan 15, 2026
Amcor PLC
NYSE:AMCR
1-for-5
/5
8.41 8.41 USD N/A
Jan 8, 2026
Sumitomo Realty & Development Co Ltd
OTC:SURYY
2-for-1
x2
25.635 25.635 USD N/A
Dec 30, 2025
Adicet Bio Inc
NASDAQ:ACET
1-for-16
/16
0.4921 0.4921 USD 7.93 7.93 USD
Load More

Portage Biotech Inc
Glance View

Market Cap
10.7m USD
Industry
Biotechnology

Portage Biotech, Inc. is a biotechnology company, which enables research and development to produce clinical programs and maximize potential returns. The company is headquartered in Toronto, Ontario and currently employs 6 full-time employees. The company went IPO on 2013-10-28. The firm is advancing therapies to improve long-term treatment response and quality of life in patients with evasive cancers. The Company’s access to technologies coupled with a deep understanding of biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. The Company’s portfolio consists of six diverse platforms, with programs including invariant natural killer T cell (iNKT) agonists, which includes PORT-2 and PORT-3, therapies that activate the innate and adaptive immune system. Its portfolio also includes small molecule adenosine inhibitors, such as PORT-6, PORT-7, PORT-8 and PORT-9, which represent of targeting the adenosine pathway. Within these six platforms, the Company has 14 products in development with multiple clinical readouts.

PRTG Intrinsic Value
1.0412 USD
Overvaluation 78%
Intrinsic Value
Price
Back to Top